David A. Scheinberg

David A. Scheinberg, M.D., Ph.D. is a physician, scientist, drug developer, and entrepreneur, who is currently Vincent Astor Chair, and Chairman of the Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center (MSK).[1] He is a pioneer and inventor of targeted alpha particle therapies and alpha particle generators for use in patients with cancer.[2][3]

David A. Scheinberg
EducationCornell University BA Johns Hopkins University School of Medicine MD, PhD
Medical career
ProfessionPhysician-scientist
InstitutionsMemorial Sloan Kettering Cancer Center
Weill Cornell Medicine
Sub-specialtiesLeukemia

Career

Scheinberg received a BA from Cornell University and an MD, PhD from Johns Hopkins University School of Medicine. He is a professor of pharmacology and co-chair of the pharmacology graduate program at Weill Cornell Graduate School of Medical Sciences and a professor at the Gerstner Sloan Kettering Graduate School. He also founded and chairs the Experimental Therapeutics Center and formerly the Nanotechnology Center at MSK. He founded and is a Director of the Tri-Institutional Therapeutics Discovery Institute of MSK, Weill Cornell Medicine, and Rockefeller Universities.

In 2013 Nature Biotechnology recognized him as one of the top 20 Translational Scientists in the world.[4] Scheinberg has published more than 300 papers, chapters, or books and has more than 30 patents.

His laboratory studies cancer immunology, cellular engineering, cancer vaccines, T cell receptor mimic antibodies, and targeted nano-machines.

Memberships

Awards
  • Doris Duke Distinguished Clinical Science Professorship
  • Lucille P. Markey Scholarship
  • Emil J. Freireich Award
  • Leukemia and Lymphoma Society Translational Investigator Awards
  • CapCure Awards

References
  1. "At Work: Center for Experimental Therapeutics Chair David Scheinberg | Memorial Sloan Kettering Cancer Center". www.mskcc.org.
  2. Scheinberg, D. A.; Strand, M.; Gansow, O. A. (1982-03-19). "Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies". Science. 215 (4539): 1511–1513. Bibcode:1982Sci...215.1511S. doi:10.1126/science.7199757. ISSN 0036-8075. PMID 7199757.
  3. McDevitt, Michael R.; Ma, Dangshe; Lai, Lawrence T.; Simon, Jim; Borchardt, Paul; Frank, R. Keith; Wu, Karen; Pellegrini, Virginia; Curcio, Michael J. (2001-11-16). "Tumor Therapy with Targeted Atomic Nanogenerators". Science. 294 (5546): 1537–1540. Bibcode:2001Sci...294.1537M. doi:10.1126/science.1064126. ISSN 0036-8075. PMID 11711678. S2CID 11782419.
  4. Huggett, Brady; Paisner, Kathryn (2014-08-07). "Top 20 translational researchers in 2013". Nature Biotechnology. 32 (8): 720. doi:10.1038/nbt.2986. PMID 25101739.
  5. "David Scheinberg ASCI".
  6. "David Scheinberg AAP".
  7. "Interurban Clinical Club Members".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.